Lipid Disturbances in Psoriasis: an Update

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2010 Aug 14

PMID 20706605

Citations 59

Authors

Aldona Pietrzak

Anna Michalak-Stoma

Grazyna Chodorowska

Jacek C Szepietowski

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Citing Articles

Effects of Th1/Th17 and Th2 cytokines on lipid metabolism in differentiated keratinocytes.

Cavallo A, Camera E, Maiellaro M, Bottillo G, Mosca S, Kovacs D Front Physiol. 2025; 16:1387128.

PMID: 40046180 PMC: 11880217. DOI: 10.3389/fphys.2025.1387128.

Metabolic pathways of eicosanoids-derivatives of arachidonic acid and their significance in skin.

Biernacki M, Skrzydlewska E Cell Mol Biol Lett. 2025; 30(1):7.

PMID: 39825220 PMC: 11742234. DOI: 10.1186/s11658-025-00685-y.

Association Between Non-HDL to HDL Cholesterol Ratio (NHHR) and Psoriasis in Adults: A Cross-Sectional Study Using 2009-2014 Data.

Jiang Y, Jia M Clin Cosmet Investig Dermatol. 2024; 17:2523-2531.

PMID: 39544258 PMC: 11561548. DOI: 10.2147/CCID.S492053.

Serum Interleukin (IL)-6, Lipid Profile, and Association With Disease Severity in Patients With Psoriasis: A Cross-Sectional Study.

Sahoo S, Das K, Panda B, Pandey M, Acharya M, Meher P Cureus. 2024; 16(9):e69599.

PMID: 39429270 PMC: 11486630. DOI: 10.7759/cureus.69599.

The Impact of Statins on Disease Severity and Quality of Life in Patients with Psoriasis: A Systematic Review and Meta-Analysis.

Aleid A, Almutairi G, Alrizqi R, Nukaly H, Alkhanani J, AlHuraish D Healthcare (Basel). 2024; 12(15).

PMID: 39120229 PMC: 11311713. DOI: 10.3390/healthcare12151526.

References

Mahley R . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240(4852):622-30. DOI: 10.1126/science.3283935. View

Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K . Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005; 44(4):328-33. DOI: 10.1111/j.1365-4632.2005.02504.x. View

Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M . Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298(7):321-8. DOI: 10.1007/s00403-006-0703-z. View

CHIBOWSKA M . [Biochemical studies of serum lipids and histochemical studies on lipids of the soft palate mucosa in palatal lipidophilia and psoriasis with associated prelipidophilia]. Pol Tyg Lek. 1969; 24(1):1-4. View

Brauchli Y, Jick S, Miret M, Meier C . Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol. 2009; 160(5):1048-56. DOI: 10.1111/j.1365-2133.2008.09020.x. View

Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R . Abnormality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol. 1994; 130(4):452-6. View

Mingrone G, Greco A, Venier A, Peruzzi E, Serri F . Lipid synthesis from the liver in patients with psoriasis. Arch Dermatol Res. 1980; 268(3):271-6. DOI: 10.1007/BF00404288. View

Mallbris L, Granath F, Hamsten A, Stahle M . Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006; 54(4):614-21. DOI: 10.1016/j.jaad.2005.11.1079. View

Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U . Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford). 2004; 44(1):126-9. DOI: 10.1093/rheumatology/keh423. View

10.

Pietrzak A, Lecewicz-Torun B . Changes in the digestive system in patients suffering from psoriasis. Ann Univ Mariae Curie Sklodowska Med. 2000; 53:187-94. View

11.

Toker A, Kadi M, Yildirim A, Aksoy H, Akcay F . Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct. 2009; 27(3):176-80. DOI: 10.1002/cbf.1553. View

12.

Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F . Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001; 303(1-2):33-9. DOI: 10.1016/s0009-8981(00)00358-2. View

13.

Kinnunen P, Ehnolm C . Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 1976; 65(3):354-7. DOI: 10.1016/0014-5793(76)80145-7. View

14.

Huerta C, Rivero E, Garcia Rodriguez L . Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007; 143(12):1559-65. DOI: 10.1001/archderm.143.12.1559. View

15.

Holleran W, Feingold K, Man M, Gao W, Lee J, Elias P . Regulation of epidermal sphingolipid synthesis by permeability barrier function. J Lipid Res. 1991; 32(7):1151-8. View

16.

Yamaoka-Tojo M, Tojo T, Kosugi R, Hatakeyama Y, Yoshida Y, Machida Y . Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis. 2009; 8:41. PMC: 2768708. DOI: 10.1186/1476-511X-8-41. View

17.

Bleck O, Abeck D, Ring J, Hoppe U, Vietzke J, Wolber R . Two ceramide subfractions detectable in Cer(AS) position by HPTLC in skin surface lipids of non-lesional skin of atopic eczema. J Invest Dermatol. 1999; 113(6):894-900. DOI: 10.1046/j.1523-1747.1999.00809.x. View

18.

Fowler A, Sheu M, Schmuth M, Kao J, Fluhr J, Rhein L . Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol. 2003; 120(2):246-55. DOI: 10.1046/j.1523-1747.2003.12033.x. View

19.

Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A . Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007; 157(1):68-73. DOI: 10.1111/j.1365-2133.2007.07986.x. View

20.

Nijsten T, Wakkee M . Complexity of the association between psoriasis and comorbidities. J Invest Dermatol. 2009; 129(7):1601-3. DOI: 10.1038/jid.2009.55. View